Last reviewed · How we verify
soluble human insulin
soluble human insulin is a Rapid-acting insulin Small molecule drug developed by Novo Nordisk A/S. It is currently FDA-approved for Type 1 diabetes mellitus, Type 2 diabetes mellitus. Also known as: Actrapid®, Actrapid.
Soluble human insulin binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.
Soluble human insulin binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | soluble human insulin |
|---|---|
| Also known as | Actrapid®, Actrapid |
| Sponsor | Novo Nordisk A/S |
| Drug class | Rapid-acting insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Soluble human insulin is a rapid-acting insulin that mimics the body's natural insulin hormone. It binds to insulin receptors on muscle, fat, and liver cells, facilitating glucose transport into these cells and promoting glycogen synthesis while inhibiting gluconeogenesis. This results in decreased blood glucose concentration in patients with diabetes mellitus.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Topical Insulin Dressing on Management of Diabetic Foot Ulcers (NA)
- Vericiguat and Reverse Remodeling Indices in Heart Failure (PHASE4)
- Pharmacokinetic and Pharmacodynamic Effects of Insulex® R in Comparison to Humulin® R in Healthy Subjects (PHASE1)
- The Effect of Locally Dilvered Ciprofloxacine Loaded Injectable Platelet-rich Fibrin as an Adjunct to Non-surgical Periodontal Therapy on the Gingival Crevicular Level of Interleukin 6 (NA)
- Efficacy of Milk Product Supplemented With Bioactives in Lowering Post Meal Glucose Response (NA)
- Medium-term Effects of a Polyphenol-rich Beverage Based on Red Grape Pomace Extract on Non-alcoholic Fatty Liver Disease, Cardiometabolic Risk Profile and Gut Microbiota in Subjects with Type 2 Diabetes (NA)
- Glycemic Evaluation of Novel Staple Foods (NA)
- The Effect of Ketone Ester Supplementation and Ketogenic Diet on Brain Plasticity in Overweight/Obese Adults (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- soluble human insulin CI brief — competitive landscape report
- soluble human insulin updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI
Frequently asked questions about soluble human insulin
What is soluble human insulin?
How does soluble human insulin work?
What is soluble human insulin used for?
Who makes soluble human insulin?
Is soluble human insulin also known as anything else?
What drug class is soluble human insulin in?
What development phase is soluble human insulin in?
What are the side effects of soluble human insulin?
What does soluble human insulin target?
Related
- Drug class: All Rapid-acting insulin drugs
- Target: All drugs targeting Insulin receptor
- Manufacturer: Novo Nordisk A/S — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 1 diabetes mellitus
- Indication: Drugs for Type 2 diabetes mellitus
- Also known as: Actrapid®, Actrapid
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing